Academic Journal

Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma
Συγγραφείς: Thomas, Anne a, ∗, Virdee, Pradeep S. b, Eatock, Martin c, Lord, Simon R. d, Falk, Stephen e, Anthoney, D. Alan f, Turkington, Richard C. g, Goff, Matthew h, Elhussein, Leena b, Collins, Linda h, Love, Sharon b, Moschandreas, Joanna b, Middleton, Mark R. d, i
Πηγή: In European Journal of Cancer January 2020 124:131-141
Βάση Δεδομένων: ScienceDirect
Περιγραφή
ISSN:09598049
DOI:10.1016/j.ejca.2019.10.010